A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Primary endpoint has not been met. (Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohns Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or Clinical Remission (CDAI Score Less Than []150) at Week 26), according to results published in the Gut.
    • 16 Feb 2017 Results published in the Gut
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top